The multifunctional DDS also showed folate-targeted codelivery of docetaxel (DOC) and tissue factor pathway inhibitor 2 TFPI2, which made cancer cells more sensitive to DOC and enhanced the antitumor effect compared with monochemotherapy. Here, TFPI2 is linked to cancer.